Valuation: Abpro Holdings, Inc.

Capitalization 13.13L 11.21L 10.27L 10L 17.99L 13Cr 18.08L 1.22Cr 47.63L 5.96Cr 49.27L 48.24L 21Cr P/E ratio 2024
-2.41x
P/E ratio 2025 -3.27x
Enterprise value 13.93L 11.9L 10.9L 10.31L 19.08L 13Cr 19.18L 1.3Cr 50.53L 6.33Cr 52.27L 51.17L 22Cr EV / Sales 2024
497x
EV / Sales 2025 -
Free-Float
83.91%
Yield 2024 *
-
Yield 2025 -
1 day+6.91%
1 week+58.73%
Current month+11.97%
1 month+114.14%
3 months-69.70%
6 months-96.22%
Current year-94.74%
1 week 0.12
Extreme 0.123
0.24
1 month 0.11
Extreme 0.109
0.24
Current year 0.09
Extreme 0.0866
5.08
1 year 0.09
Extreme 0.0866
13.65
3 years 0.09
Extreme 0.0866
390
5 years 0.09
Extreme 0.0866
390
10 years 0.09
Extreme 0.0866
390
Change 5d. change 1-year change 3-years change Capi.($)
+6.91%+58.73%-96.38%-99.93% 13.13L
-0.82%-3.93%-17.36%-17.47% 4.23TCr
+0.47%+1.03%+40.86%+32.80% 3.52TCr
+2.90%-0.75%+275.32%+479.59% 3.19TCr
-1.53%-2.32%+14.40%-8.40% 2.88TCr
-1.45%-2.16%+28.40%+24.87% 2.68TCr
+2.50%+3.26% - - 1.51TCr
+3.68%-0.98%+232.53%+4,188.18% 1.35TCr
+2.33%+0.98%+138.55%+118.53% 1.28TCr
-0.64%-1.97%+6.67%-1.97% 1.21TCr
Average +1.43%-0.46%+69.22%+524.02% 2.19TCr
Weighted average by Cap. +0.46%-1.62%+76.96%+364.81%

Financials

2024 2025
Net sales 2L 2L 1L 1L 3L 1.75Cr 3L 17.05L 7L 83.11L 7L 7L 2.89Cr -
Net income -72.32L -61.76L -56.59L -53.5L -99.06L -69Cr -99.58L -6.74Cr -2.62Cr -33Cr -2.71Cr -2.66Cr -114.16Cr -28.92L -24.7L -22.63L -21.39L -39.61L -28Cr -39.82L -2.69Cr -1.05Cr -13Cr -1.09Cr -1.06Cr -46Cr
Net Debt 5L 4L 4L 4L 7L 4.57Cr 7L 44.54L 17.34L 2.17Cr 17.94L 17.56L 7.55Cr 80T 68.32T 62.6T 59.18T 1L 76.56L 1L 7L 3L 36.33L 3L 3L 1.26Cr
Logo Abpro Holdings, Inc.
Abpro Holdings, Inc. is a biotechnology company. The Company is advancing a pipeline of next generation antibody therapies for human epidermal growth factor receptor 2 (HER2)+cancers, non-HER2+ gastric and liver cancer, and wet age-related macular degeneration (AMD) and diabetic macular edema (DME). These antibodies are developed using the Company’s proprietary DiversImmune platform. Its two lead product candidates, ABP-102 and ABP-201, feature its next generation tetravalent antibody format (TetraBi antibody format), which binds to two different targets with two distinct binding sites per target. ABP-102 is designed to redirect a patient’s immune system to fight cancer by engaging T cells through co-targeting HER2, and CD3, T-cell co-receptor. ABP-201 is designed to block blood vessel formation and normalize damaged vessels through co-targeting VEGF and ANG-2. It plans to develop ABP-201 to treat vascular disease of the eye, focusing on wet age-related macular degeneration (Wet AMD).
Employees
2
Date Price Change Volume
13/26/13 0.2227 $ +6.91% 17,967
12/26/12 0.2083 $ +26.99% 14,859
11/26/11 0.1640 $ -13.66% 21,807
08/26/08 0.1900 $ -9.52% 6,633
07/26/07 0.2100 $ +49.68% 13,509

Quarterly revenue - Rate of surprise